LB-DTK-COV19

LB-DTK-COV19 is an autologous T-cell therapy developed by LucasBio for the treatment of prolonged SARS-CoV-2 infection, particularly in moderately immunocompromised patients who are refractory to standard care. The product consists of T cells harvested from the patient, expanded ex vivo, and sensitized to SARS-CoV-2 antigens. Upon re-infusion, these antigen-specific T cells are intended to recognize and eliminate virus-infected cells, thereby reducing viral load and alleviating clinical symptoms. It is currently being evaluated in clinical trials for its safety and efficacy in clearing persistent viral infections.

Other names

autologous SARS-CoV-2-specific T cell therapy